Cybin (HELP) Income towards Parent Company (2020 - 2022)
Cybin (HELP) reported Income towards Parent Company of $4.6 million for Q2 2022, up 146.6% quarter-over-quarter from -$9.8 million in Q1 2021.
Cybin (HELP) Income towards Parent Company (2020 - 2022) Analysis & Trends
Cybin has reported Income towards Parent Company for 3 years, with the latest figure at $4.6 million in Q2 2022.
- For the quarter ending Q2 2022, Income towards Parent Company changed N/A year-over-year to $4.6 million; the trailing twelve-month figure through Feb 2023 stood at $4.6 million (changed N/A YoY), and the FY2023 full-year result was -$20.3 million, changed N/A from the prior year.
- Income towards Parent Company for Q2 2022 stood at $4.6 million, up from -$9.8 million in the prior quarter.
- The five-year high for Income towards Parent Company was $4.6 million in Q2 2022, with the low at -$9.8 million in Q1 2021.
- Historically, Income towards Parent Company has averaged -$3.8 million across 3 years, with a median of -$3.0 million in 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cybin | 75.42 Mn | 75.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2022 | 4.55 Mn |
| Mar 31, 2021 | -9.77 Mn |
| Dec 31, 2020 | -8.72 Mn |
| Sep 30, 2020 | -1.92 Mn |
| Jun 30, 2020 | -3.04 Mn |